About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

A study has shown that bortezomib can enhance the activity of doxorubicin-based chemotherapy for the treatment of activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). This ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

Managing R/R-transformed DLBCL remains a challenge, as affected patients have an approximate 27% chance of 4-year event-free survival and a 39% chance of overall survival. 2 Atezolizumab is a ...